Rabourn Amy Zaremba Sells 2,816 Shares of Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) insider Rabourn Amy Zaremba sold 2,816 shares of Opus Genetics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $5.25, for a total value of $14,784.00. Following the sale, the insider owned 190,312 shares in the company, valued at $999,138. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Opus Genetics Stock Down 2.9%

Shares of IRD traded down $0.14 during trading on Wednesday, reaching $4.66. The company’s stock had a trading volume of 922,949 shares, compared to its average volume of 1,007,191. The company has a market cap of $331.56 million, a price-to-earnings ratio of -5.68 and a beta of 0.45. The company has a fifty day moving average of $3.30 and a two-hundred day moving average of $2.39. Opus Genetics, Inc. has a twelve month low of $0.65 and a twelve month high of $5.30.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Occudo Quantitative Strategies LP acquired a new position in shares of Opus Genetics in the 4th quarter valued at about $25,000. Comerica Bank acquired a new stake in Opus Genetics during the first quarter worth about $29,000. Virtu Financial LLC acquired a new stake in Opus Genetics during the fourth quarter worth about $34,000. Raymond James Financial Inc. lifted its holdings in Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Johnson Investment Counsel Inc. bought a new position in Opus Genetics in the fourth quarter worth about $40,000. 14.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IRD has been the topic of a number of research analyst reports. Piper Sandler began coverage on shares of Opus Genetics in a report on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price objective for the company. BTIG Research upped their target price on shares of Opus Genetics from $7.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Chardan Capital lifted their price target on Opus Genetics from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. Brookline Capital Acquisition raised Opus Genetics to a “strong-buy” rating in a report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $9.33.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.